Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
(Sapanisertib + serabelisib) by Faeth Therapeutics for Endometrial Cancer: Likelihood of Approval
(Sapanisertib + serabelisib) is under clinical development by Faeth Therapeutics and currently in Phase I for Endometrial Cancer. According to...
FTH-002 by Faeth Therapeutics for Rectal Cancer: Likelihood of Approval
FTH-002 is under clinical development by Faeth Therapeutics and currently in Phase I for Rectal Cancer. According to GlobalData, Phase...
(Sapanisertib + serabelisib) by Faeth Therapeutics for Solid Tumor: Likelihood of Approval
(Sapanisertib + serabelisib) is under clinical development by Faeth Therapeutics and currently in Phase I for Solid Tumor. According to...